NFKB1 and cholangiocarcinoma: Inhibition of NF-κB action by DHMEQ suppressed proliferation of five human CCA cell lines (KKU-M139, KKU-M156, KKU-M213, KKU-M214 and KKU-100) and induced cell cycle arrest at G2/M phase.